Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2006 September;50(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2006 September;50(3):236-42

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

REVIEWS  INFLAMMATION AND INFECTION PART 2FREEfree


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2006 September;50(3):236-42

Copyright © 2006 EDIZIONI MINERVA MEDICA

language: English

Receptor targeting agents for imaging inflammation/infection: where are we now?

Signore A. 1, 2, Chianelli M. 2, 3, D’Alessandria C. 1, Annovazzi A. 1, 2

1 Department of Nuclear Medicine 2nd Faculty of Medicine La Sapienza University of Rome, Rome, Italy 2 Department of Nuclear Medicine and Molecular Imaging University Medical Center, Groningen, The Netherlands 3 Nuclear Medicine Unit Regina Apostolorum Hospital, Albano, Rome, Italy


FULL TEXT  


Over the past 20 years, radiopharmaceutical research has brought to market a wide variety of drugs that aid in the management of infection and inflammation. Finding the best clinical application for existing radiopharmaceuticals can be a challenging task, as clinicians now have to choose from an array of many different radiopharmaceuticals, each suited to identify a specific type of inflammation. With this review, we describe the features of receptor-targeting agents and present the main advantages and limitations to their application in the diagnosis of inflammation and infection. The receptor-specific agents described here include peptides and antibodies as well as radiolabeled antibodies employed for the specific targeting of neutrophils, bacteria, lymphocytes, and molecules involved in inflammatory processes. Because these agents bind to specific receptors, they allow the mapping of receptor expression in vivo. Such mapping represents the future of nuclear medicine imaging, as it aids in diagnosing the type of inflammation, in therapy decision-making, in selecting suitable candidates for therapy, and in evaluating treatment efficacy.

top of page

Publication History

Cite this article as

Corresponding author e-mail